Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03729245
Title A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Nektar Therapeutics

renal cell carcinoma


Cabozantinib + Sunitinib

Nivolumab + NKTR-214

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.